AtriCure (ATRC) Reports In-Line Q3 EPS; Guides FY15 Revenue Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
AtriCure Reports Third Quarter 2015 Financial Results
October 27, 2015 4:01 PM EDTRevenue of $31.4 million up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million up 23.0% International sales of $6.7 million up 2.1% as reported, 13.2% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced third quarter 2015 financial results.
We are pleased with our performance in the third quarter and excited about our prospects for sustained growth, said Mike Carrel, President and Chief Executive... More
